Funding news
InflaRx logo

InflaRx Raises $150

Recently funded · $150.0M UnknownHospitals and Health CareDEView source

Get the full InflaRx company profile

Access contacts, investors, buying signals & more

Open in Dashboard

Biopharmaceutical company InflaRx, which specializes in pioneering anti-inflammatory therapeutics, has secured $150.0M in new capital. The funding comes as the company continues to advance its proprietary anti-C5a and anti-C5aR technologies, aiming to develop highly potent inhibitors for various inflammatory diseases.

Founded in 2007, InflaRx is known for its lead product candidate, vilobelimab, a novel anti-C5a monoclonal antibody. It is also developing INF904, an orally administered C5a receptor inhibitor, with operations spanning Germany and the U.S.

May 6 - 8, 2026 headlines: InflaRx's $150 Million Public Offering, ParcelBio's $13 Million Seed Round, Pharvaris's $115 Million Public Offering, Artiva's $300 Million Public Offering, a daily summary of financings for therapeutic biotechnology company executives and investors - www.collabrityreport.comInflaRx ParcelBio Pharvaris Artiva Biotherapeutics

Other Germany companies recently funded

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
GRAIL logo

GRAIL

United States

$7.1B
4
Illumina logo

Illumina

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Unknown rounds

Companies that recently closed a Unknown round.

#CompanyAmount
1
Founders First Capital Partners logo

Founders First Capital Partners

United States

$3.9M
2
Starsight Energy logo

Starsight Energy

Nigeria

$15.0M
3
Ethos logo

Ethos

United States

$22.8M
4
Maurice & Nora logo

Maurice & Nora

Belgium

$1.2M
5
waterdrop® logo

waterdrop®

Austria

$117.8M